While mutations in IDH1 and IDH2 enzymes, typical producers of 2-HG in certain cancers, are rare in CRC, our findings suggest that a glycolytic phenotype may promote the 2-HG accumulation even without these mutations. Here, IDH2 is linked to cancer.